Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13221MR)

This product GTTS-WQ13221MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13221MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ546MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ2488MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ4633MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ14679MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ4471MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ3139MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ12763MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ10033MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA L19-131 I
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW